Thank today. thank you for and us you David. joining Hello, everyone,
of and Let supply completed These related inflation, we for by margins optimization and our our support margins goals despite with kept effects global the to saying gross lingering better. and the XX% growth me chain, designed start to in down disclosed stated that cost reductions. revenue EBITDA the previously are actions high-teens portfolio currency XX% the and or heads
of down let's go for Adjusting at to strong the down year. we shipments presentation the X revenue impact Reported up. recovering a currency prior very was for million the not slide in the revenue pre-clinical with seen million, catch to revenues majority of QX The highlights from Now $X XX% to QX quarter. later quarter was look from impact for in XX%. time a demand were for $XX.X in though order
portfolio for improved historical low-margin in gross a remaining with wind growth a Adjusted products XX% as margin recovered to strong XXXX. product margins obsolete substantially they spite the down. start order Strong gross to points consistent with of
operating XX%. margin in came Adjusted at
GAAP of measured year. adjusted measurements down In per the from operations measured cash $X.XX appendix very to the Going $X.X find be EBITDA, And from which measured million. flow we'll adjusted last reporting $X.XX EPS you'll XX% bridge a QX forward, Adjusted strong non-GAAP EBITDA. in from revenue. share,
exchange revenue family. first the of digits in We offset slowness technology the molecular QX when which up slide cellular globally. in to in Asia were solid testing products Americas. for product X, Now by shows XXXX by was our Pacific, adjusted growth let's flat slide quarter the had reflect look rates. This adjusted roughly table, move Cell was take double revenue currency. with based to Starting revenue the XXXX a the at QX row
last quarter by decreasing rotation products from revenues the with the about of continued products saw same discontinued low-margin year. $XXX,XXX out We versus
We increase Electroporation as exciting for forward, going bioproduction. by are products demand new and with seeing such services new augmented consumables
a QX prior of in currency quarter, our QX. XX% constant in early strong the historically Recovering were down came QX in in and down much were year. the pre-clinical in inhalation order though, Globally products later somewhat the Next, from improvement revenue telemetry shipments quarter. and
quarter compared and ratio impact later of a China pound but in point strong lockdown QX strong drove to British a earlier. further strong $X to a for dollar demand demand the order shipments, million, The with solid euro delayed The lockdowns start much, XXXX. spoke book-to-bill of order recovery U.S. the with currency eased. the I growth order strong later recovering as quarter in Overall, help the didn't
Now you tell in slide the let's launches quarter. of some new can to move about the X, exciting so product I
me let little minute bit start, slide. about a explain this a take I Before to
the three to our optimized critical the drug of Over last continuum. we've product therapy areas and years, offerings
now to bridge discovery more or offering With new and widely also research recently, research we're and electrofusion cellular the both products molecular companies a technology new method Electroporation bioproduction or on is of a drug top academic therapy, enabling focusing vaccine. used compounds And create biopharma universities. where to by
and systems regulatory required biotech, prior and the use. clinical to has critical wirelessly utilized safety ability This and behavioral collect models. clinical primarily filings for CRO offer measure physiologic preclinical been pharma, information from data human to Our the and large longitudinal for animal academics studies
data future. also to Our post enterprise in reduction, the testing pools efficient AI-related the see coming large future data we software for as preclinical during processing for generation collected access report and provides and
significant QX a quickly order Reaction Chambers Cellular is top to primarily expected Molecular million expanded consumption $X our of and shipments received Flatpack to unique by in bio-production. augmented large system a XXXX our we with company ramp order Starting pharma annually, from for QX by of This Electroporation for and in BTX driven Technologies, began configured services.
in proposition to of from this addition revenue ongoing and provide required to often We're the bio-production, emerging BTX create the quantities system, in production stream that vaccines. those today Electroporation which of the other benefits potential has in historically and therapeutics and excited about to research research pharmaceutical substantial initial discovery. consumable is used BTX value in for development strength and Flatpack
on Spectrophotometer This to late well-known models, academic and penetrate new in QX. building companies replaces top shipping Second, our sites better designed we name. CRO existing our introduced, the started and pharma is and and three Premium ultra-spec UXXXX system
market continuing preclinical, Lastly, manual draws drive our and sampling. the and monitoring monitoring new leadership wireless in inconvenience implant continuous for inherent of for cost, continuous Glucose to periodic This blood variability in monitoring avoids Implant. we continuous glucose levels launched allows "Exclusive"
to diabetes. companies of This solutions and our implants the new began of for growth line Glucose academic obesity in an driver labs labs government problems will incremental XXXX beyond. late of new the QX shipping and and pursuit and services monitoring in is in pharma of expected growth and in be consumables and augment ever-growing
turn I'll CFO, Jennifer to our the look at Now interim a for over Jen? Cote, key call quick financials.
